Cellectar Biosciences (CLRB) Current Leases (2010 - 2026)
Cellectar Biosciences (CLRB) posted Current Leases of $100189.0 for Q4 2025, up 4.33% sequentially from $96034.0 in Q3 2025, and up 18.68% YoY from $84417.0 in Q4 2024.
Cellectar Biosciences (CLRB) Current Leases (2010 - 2026) Analysis & Trends
Cellectar Biosciences has reported Current Leases for 16 years, with the latest figure at $100189.0 in Q4 2025.
- Quarterly Current Leases rose 18.68% year-over-year to $100189.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $100189.0 (up 18.68% YoY) and the FY2025 annual result came in at $100189.0, up 18.68% from the prior year.
- Current Leases grew to $100189.0 in Q4 2025 per CLRB's latest filing, from $96034.0 in the prior quarter.
- Over five years, Current Leases peaked at $148200.0 in Q3 2022 and troughed at $50847.0 in Q4 2022.
- A 5-year average of $95670.8 and a median of $90084.0 in 2025 frame the typical range for Current Leases.
- The sharpest annual moves came in 2023 and 2024: Current Leases tumbled 63.39% in 2023, then jumped 44.79% in 2024.
- Over 5 years, Current Leases stood at $135449.0 in 2021, then sank by 62.46% to $50847.0 in 2022, then rose by 15.99% to $58979.0 in 2023, then surged by 43.13% to $84417.0 in 2024, then gained by 18.68% to $100189.0 in 2025.
- According to Business Quant data, Current Leases over the past three periods registered $100189.0, $96034.0, and $92022.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 21.95 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 45.93 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Cellectar Biosciences | 6.73 Mn | 6.73 Mn | - | 2,030.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2,030.00 |
| Dec 31, 2025 | 100,189.00 |
| Sep 30, 2025 | 96,034.00 |
| Jun 30, 2025 | 92,022.00 |
| Mar 31, 2025 | 88,146.00 |
| Dec 31, 2024 | 84,417.00 |
| Sep 30, 2024 | 80,821.00 |
| Jun 30, 2024 | 77,348.00 |
| Mar 31, 2024 | 73,994.00 |
| Dec 31, 2023 | 58,979.00 |
| Sep 30, 2023 | 56,263.00 |
| Jun 30, 2023 | 53,640.00 |
| Mar 31, 2023 | 51,106.00 |
| Dec 31, 2022 | 50,847.00 |
| Sep 30, 2022 | 148,200.00 |
| Jun 30, 2022 | 143,843.00 |
| Mar 31, 2022 | 139,594.00 |
| Dec 31, 2021 | 135,449.00 |
| Sep 30, 2021 | 131,406.00 |
| Jun 30, 2021 | 127,476.00 |